BIOTRONIK published final results of the landmark TRUST Trial (Lumax-T/Lumos-T Safely RedUceS RouTine Office Device Follow-up) in the July 27, 2010 issue of Circulation. BIOTRONIK Home Monitoring® is the industry’s first and most advanced wireless remote monitoring system for patients with cardiac devices.
The article, ”Efficacy and Safety of Automatic Remote Monitoring for ICD Follow-Up: The TRUST Trial,” demonstrates the benefits of home monitoring in the safe reduction of conventional clinic follow-up visits, as well as in the early detection of patient clinical events, including asymptomatic atrial fibrillation. Further, home monitoring can extend the time between routine in-office follow-ups, and is the only system having FDA and CE approval to claim these benefits. Developed by a steering committee of U.S. electrophysiologists, with 1,450 patients enrolled and randomised in 102 North American sites, TRUST is the first large-scale prospective cardiac rhythm management study to prove remote monitoring and rapid detection of symptomatic and asymptomatic cardiac events in a prospective, randomised trial. TRUST used BIOTRONIK home monitoring, an automatic, wireless system that performs daily telemetric surveillance of the patient and reports the technical status of the implanted device without requiring patient activation.